Exact Sciences Co. (NASDAQ:EXAS) insider Jacob A. Orville sold 1,696 shares of the stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $143.38, for a total transaction of $243,172.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
NASDAQ EXAS opened at $142.32 on Tuesday. The stock has a market capitalization of $24.07 billion, a price-to-earnings ratio of -64.40 and a beta of 1.64. Exact Sciences Co. has a one year low of $35.25 and a one year high of $159.54. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.35 and a quick ratio of 6.04. The business’s fifty day moving average is $143.72 and its 200-day moving average is $115.91.
Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, February 15th. The medical research company reported ($2.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($2.60). Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. Research analysts expect that Exact Sciences Co. will post -1.56 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its stake in Exact Sciences by 6.0% in the 4th quarter. International Assets Investment Management LLC now owns 4,184 shares of the medical research company’s stock valued at $554,000 after acquiring an additional 237 shares during the period. Columbus Circle Investors bought a new stake in Exact Sciences in the 4th quarter valued at about $28,257,000. JGP Global Gestao de Recursos Ltda. raised its stake in Exact Sciences by 3.4% in the 4th quarter. JGP Global Gestao de Recursos Ltda. now owns 3,487 shares of the medical research company’s stock valued at $462,000 after acquiring an additional 114 shares during the period. Thrivent Financial for Lutherans bought a new stake in Exact Sciences in the 3rd quarter valued at about $207,000. Finally, California State Teachers Retirement System raised its stake in Exact Sciences by 2.3% in the 3rd quarter. California State Teachers Retirement System now owns 272,781 shares of the medical research company’s stock valued at $27,810,000 after acquiring an additional 6,194 shares during the period. Institutional investors and hedge funds own 90.39% of the company’s stock.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services.
Recommended Story: Return On Assets
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.